Clinical Trial Update: Efficacy and Safety of Angong Niuhuang Wan for Stroke [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update for Angong Niuhuang Wan evaluating efficacy and safety in stroke and TIA patients across Phase 2 and Phase 3.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stroke
• Transient Ischemic Attack

Drugs mentioned

• Angong Niuhuang Wan (null)

Snippet

Sponsor: Chinese University of Hong Kong | Conditions: Stroke (CVA) or TIA | Phase 2, Phase 3 | Status: UNKNOWN